Menu

Oxford University to Study Marijuana

Academics partner with a biotech firm to investigate cannabinoids and develop potential therapeutics.

Mar 20, 2017
Kerry Grens

PIXABAY, FOTOBIASOxford University in the U.K. and biotech company Oxford Cannabinoid Technologies are launching a new line of research into marijuana’s potential for treating various ailments, including cancer and chronic pain. In the U.S., some states have legalized medical or recreational use of the drug, but marijuana is currently not legal in the U.K.

“Cannabinoid research has started to produce exciting biological discoveries,” Ahmed Ahmed, a professor of Gynaecological Oncology at Oxford University, said in a press release. “This field holds great promise for developing novel therapeutic opportunities for cancer patients.”

In addition to cancer, the co-called Cannabis Research Plan, which will begin with a roughly $12.4 million investment from the biotech firm, will also study cannabinoids’ effects on pain and inflammatory diseases.

Oxford neuroscientist Zameel Cader told The Independent the endocannabinoid system—the signaling pathways that include receptors that detect the psychoactive components of marijuana—is important for both brain function and immune responses. “We know that’s particularly important for many neurological disorders. It’s really an area of huge untapped potential.”

 

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

Slice® Safety Cutters for Lab Work

Slice® Safety Cutters for Lab Work

Slice cutting tools—which feature our patent-pending safety blades—meet many lab-specific requirements. Our scalpels and craft knives are well suited for delicate work, and our utility knives are good for general use.

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.